MetLife Investment Management LLC Trims Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

MetLife Investment Management LLC reduced its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 1.6% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 56,707 shares of the company’s stock after selling 895 shares during the period. MetLife Investment Management LLC owned about 0.06% of Neurocrine Biosciences worth $6,534,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. Ashton Thomas Private Wealth LLC purchased a new stake in shares of Neurocrine Biosciences in the second quarter valued at $28,000. Innealta Capital LLC purchased a new stake in Neurocrine Biosciences in the 2nd quarter valued at about $30,000. EdgeRock Capital LLC acquired a new position in shares of Neurocrine Biosciences during the 2nd quarter valued at about $35,000. Blue Trust Inc. increased its stake in shares of Neurocrine Biosciences by 171.9% during the 3rd quarter. Blue Trust Inc. now owns 348 shares of the company’s stock valued at $40,000 after acquiring an additional 220 shares during the last quarter. Finally, Plato Investment Management Ltd boosted its position in shares of Neurocrine Biosciences by 44.1% in the second quarter. Plato Investment Management Ltd now owns 425 shares of the company’s stock worth $59,000 after acquiring an additional 130 shares during the last quarter. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on NBIX shares. JPMorgan Chase & Co. boosted their price target on Neurocrine Biosciences from $173.00 to $181.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. Oppenheimer increased their price objective on shares of Neurocrine Biosciences from $216.00 to $219.00 and gave the stock an “outperform” rating in a research report on Friday, August 2nd. Citigroup lifted their target price on shares of Neurocrine Biosciences from $150.00 to $158.00 and gave the company a “neutral” rating in a report on Friday, August 2nd. StockNews.com downgraded Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a report on Friday, November 1st. Finally, Raymond James reaffirmed an “outperform” rating and issued a $155.00 target price on shares of Neurocrine Biosciences in a research report on Thursday, October 10th. Five analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Neurocrine Biosciences has a consensus rating of “Moderate Buy” and an average target price of $163.91.

Neurocrine Biosciences Stock Performance

Shares of NBIX stock opened at $126.75 on Friday. The stock has a market capitalization of $12.83 billion, a price-to-earnings ratio of 33.98 and a beta of 0.35. Neurocrine Biosciences, Inc. has a one year low of $110.95 and a one year high of $157.98. The company’s 50-day simple moving average is $119.26 and its 200-day simple moving average is $131.61.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.